Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
A Phase III, Multicenter, Randomized, parallel-group study to asses the efficacy and saftey of double-blind pasireotide LAR 40 mg and pasireotide LAR 60 mg versus open lable octreotide LAR or lanreotide ATG in patients with inadequately controlled acromegaly.	Novartis	Ongoing	Pasireotide	3	CSOM230C2402	King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Jeddah)
An Open-lable, Multicenter, expanded access study of INC424 for patients with primary myelofibrosis (PMF) or post polycythemia myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibrosis (PET-MF).	Novartis	Ongoing	Ruxolitinib	3b	CINC424A2401	King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Medical City NG (Jeddah)
A Randomized, Open-label, Multicentral, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)	Novartis	Ongoing	Deferasirox / Defearisox new formula	2	CICL670F2201	King Khalid University Hospital (Riyadh), King Fahad University Hospital (Al-Khobar), King Abdulaziz University Hospital (Jeddah), King Fahad Specialist Hospital (Dammam)
Daily practice treatment and Influence of Visanne on the patient Assessment of quality of life parameters	Bayer	Completed	Visanne	4	VS1101	King Khalid University Hospital (Riyadh), Soliman Fakeeh Hospital (Jeddah)
An Open-Label, Randomized Naturalistic Study to Evaluate the Incidence of Hypoglycemia Comparing Sitagliptin With Sulfonylurea Treatment in Patients With Type 2 Diabetes During Ramadan Fasting	MSD	Completed	Sitagliptin	4	MK0431-263	Al-Noor Specialist Hospital (Makkah), Armed Forces Hospital (Al-Hada), King Fahad University Hospital (Al-Khobar), Riyadh Care Hospital, Al Alam Medical Center (Riyadh)
A 20-week Study Comparing Patient-adjusted Versus Physician-adjusted Titration of BIAsp 30 Combined With Metformin in Type 2 Diabetes Patients Uncontrolled on NPH Insulin	Novonordisk	Completed	BIAsp 30 / Metformin	4	BIAsp 3968	King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz University Hospital (Jeddah), Armed Forces Hospital (Al-Hada)
A multicentre, prospective observational cohort study to assess the effects of vildagliptin relative to sulphonylurea as dual therapy with metformin (or as monotherapy) in Muslim patients with type 2 diabetes fasting during Ramadan	Novartis	Completed	Vildagliptin / Sulphonylurea / Metformin	4	CLAF237A-MAX-AE-02	Soliman Fakeeh Hospital (Jeddah)
A Multicenter, Prospective, Observational, Non-Interventional Cohort Study Evaluating On-Treatment Predictors of Response in Subjects With HBeAg Positive and HBeAg Negative Chronic Hepatitis B Receiving Therapy With PEGASYS(R) (Peginterferon Alfa-2a 40KD)	Roche	Completed	Pegasys	4	MV22009	King Fahad University Hospital (Al-Khobar), Armed Forces Hospital (Kharj)
UNraveling nAMD real life Clinical management and Outcome with intraVitrEal Ranibizumab injection – A retrospective analysis (UNCOVER)	Novartis	Completed	Ranibizumab	4	CRFB0021	King Khaled Eye Specialist Hospital (Riyadh)
A double blind, Double Dummy, Randomized, Multi-Centre study to assess the tolerability and Efficacy Profile of Vildagliptin Compared to Gliclazide as Dual Therapy with Metformin in Muslim Patients with Type 2 Diabetes Fasting During Ramadan.	Novartis	Completed	Vildagliptin /Gliclazide / Metformin	4	CLAF237A2411	King Fahad University Hospital (Al-Khobar)_ King Abdulaziz Medical City NG (Riyadh)